Imidazo[2,1-<i>b</i>]benzothiazol Derivatives as Potential Allosteric Inhibitors of the Glucocorticoid Receptor
作者:Michael S. Christodoulou、Federico Dapiaggi、Francesca Ghiringhelli、Stefano Pieraccini、Maurizio Sironi、Marianna Lucafò、Debora Curci、Giuliana Decorti、Gabriele Stocco、Chandra Sekhar Chirumamilla、Wim Vanden Berghe、Patrick Balaguer、Benoît Y. Michel、Alain Burger、Egle M. Beccalli、Daniele Passarella、Nadine Martinet
DOI:10.1021/acsmedchemlett.7b00527
日期:2018.4.12
of imidazo[2,1-b]benzothiazole and imidazo[2,1-b]benzoimidazole derivatives were identified for their ability to modulate GCR transactivation and anti-inflammatory transrepression effects utilizing GCR and NF-κB specific reporter gene assays. Modeling studies on the crystallographic structure of the GCR ligand binding domain provided three new analogues bearing the tetrahydroimidazo[2,1-b]benzothiazole
糖皮质激素受体(GCR)反式激活报告基因试验被用作对1200种化合物的多元化文库的初步高通量筛选,以评估其作为GCR拮抗剂的作用。一类咪唑并[2,1- b ]苯并噻唑和咪唑并[2,1- b ]苯并咪唑衍生物利用GCR和NF-κB特异的报告基因检测方法,具有调节GCR反式激活和抗炎性抑制作用的能力。GCR配体结合域的晶体结构的模型研究提供了三个带有四氢咪唑[2,1- b]的新类似物能够在地塞米松(DEX)存在下拮抗GCR的]苯并噻唑支架,并且还定义了它们在GCR结构中的假定结合。在用新类似物处理的细胞上,GCR本身及其靶基因GILZ的mRNA水平测量均显示出GCR反式激活抑制作用,因此暗示了GCR的潜在变构抑制作用。